What Did This CEO Just Do with Personal Shares of Adamis Pharma (NASDAQ: ADMP)?

By Carrie Williams

Today, the President & CEO of Adamis Pharma (ADMPResearch Report), Dennis Phd Carlo, sold shares of ADMP for $30.04K.

In addition to Dennis Phd Carlo, 2 other ADMP executives reported Sell trades in the last month.

See today’s analyst top recommended stocks >>

Based on Adamis Pharma’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $4.15 million and GAAP net loss of $12.81 million. In comparison, last year the company earned revenue of $2.84 million and had a GAAP net loss of $8.03 million. Currently, Adamis Pharma has an average volume of 424.5K.

Based on 3 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $6.40, reflecting a 199.1% upside.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development and sales of pharmaceutical, specialty biopharmaceutical and other drug products. It offers Symjepi product for allergy, respiratory, opioid overdose, and erectile dysfunction (ED), markets.